Your browser doesn't support javascript.
loading
RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
Yoo, Sun-Mi; Lee, Cheol-Jung; An, Hyun-Jung; Lee, Joo Young; Lee, Hye Suk; Kang, Han Chang; Cho, Sung-Jun; Kim, Seung-Min; Park, Juhee; Kim, Dae Joon; Cho, Yong-Yeon.
Afiliación
  • Yoo SM; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. apple_ma@naver.com.
  • Lee CJ; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. veritas0613@naver.com.
  • An HJ; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. anhyunjung11@gmail.com.
  • Lee JY; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. joolee@catholic.ac.kr.
  • Lee HS; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. sianalee@catholic.ac.kr.
  • Kang HC; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. hckang@catholic.ac.kr.
  • Cho SJ; Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, USA. choxx500@umn.edu.
  • Kim SM; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. sonatamao@naver.com.
  • Park J; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. pjhlove6385@naver.com.
  • Kim DJ; Department of Molecular Science, School of Medicine, University of Texas Rio Grande Valley, Edinburg Research Education Building, Room 2.112, 1214, W. Schunior St, Edinburg, TX 78541, USA. dae.kim@utrgv.edu.
  • Cho YY; Integrated Research Institute of Pharmaceutical Sciences, BRL & BK21 Plus team, Pharmaceutical Biochemistry, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Korea. yongyeon@catholic.ac.kr.
Int J Mol Sci ; 20(8)2019 Apr 23.
Article en En | MEDLINE | ID: mdl-31018569
Ribosomal S6 kinase 2 (RSK2), regulated by Ras/Raf/MEKs/ERKs, transmits upstream activation signals to downstream substrates including kinases and transcription and epigenetic factors. We observed that ELK members, including ELK1, 3, and 4, highly interacted with RSK2. We further observed that the RSK2-ELK3 interaction was mediated by N-terminal kinase and linker domains of RSK2, and the D and C domains of ELK3, resulting in the phosphorylation of ELK3. Importantly, RSK2-mediated ELK3 enhanced c-fos promoter activity. Notably, chemical inhibition of RSK2 signaling using kaempferol (a RSK2 inhibitor) or U0126 (a selective MEK inhibitor) suppressed EGF-induced c-fos promoter activity. Moreover, functional deletion of RSK2 by knockdown or knockout showed that RSK2 deficiency suppressed EGF-induced c-fos promoter activity, resulting in inhibition of AP-1 transactivation activity and Ras-mediated foci formation in NIH3T3 cells. Immunocytofluorescence assay demonstrated that RSK2 deficiency reduced ELK3 localization in the nucleus. In MDA-MB-231 breast cancer cells, knockdown of RSK2 or ELK3 suppressed cell proliferation with accumulation at the G1 cell cycle phase, resulting in inhibition of foci formation and anchorage-independent cancer colony growth in soft agar. Taken together, these results indicate that a novel RSK2/ELK3 signaling axis, by enhancing c-Fos-mediated AP-1 transactivation activity, has an essential role in cancer cell proliferation and colony growth.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factores de Transcripción / Neoplasias de la Mama / Regulación Neoplásica de la Expresión Génica / Transformación Celular Neoplásica / Proteínas Proto-Oncogénicas / Proteínas Proto-Oncogénicas c-fos / Proteínas Quinasas S6 Ribosómicas 90-kDa Límite: Animals / Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factores de Transcripción / Neoplasias de la Mama / Regulación Neoplásica de la Expresión Génica / Transformación Celular Neoplásica / Proteínas Proto-Oncogénicas / Proteínas Proto-Oncogénicas c-fos / Proteínas Quinasas S6 Ribosómicas 90-kDa Límite: Animals / Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article Pais de publicación: Suiza